INTRODUCTION {#s1}
============

Mast cells are located in peripheral tissues and regulate innate and adaptive immune responses \[[@R1]\] by producing mediators (e.g., histamine, proteases, leukotrienes or cytokines) that recruit and activate, granulocytes, dendritic cells, T-lymphocytes and other cells \[[@R1]--[@R5]\]. They are critical in type I hypersensitivity and therefore central to the pathogenesis of allergic diseases \[[@R6]\]. The participation of mast cells in the pathogenesis of autoimmune diseases has been reported \[[@R7]\] and refuted \[[@R8]\]. Mast cells can produce pathogenetically relevant cytokines such as IL-1β, IL-6, IL-13, IL-17 and TNFα \[[@R9]\]. It has also been demonstrated that mast cells are critical regulators of the tumor microenvironment \[[@R10]\] and that expression of constitutively active Ras- or c-Kit-mutants leads to development of mast cell tumors \[[@R11], [@R12]\].

The most extensively characterized trigger for mast cell activation is crosslinking of the Fcε-receptor-I (FcεRI) resulting in the release of mediators including histamine, proteases, cytokines, and chemokines \[[@R13]\].

Mast cells express TLR/interleukin-1 (IL-1) receptor (TIR) family members including TLR4 and the IL-33-receptor (IL-33R) \[[@R1], [@R14]\]. IL-33 induces antigen-independent activation of mast cells \[[@R15]\] via the canonical NFκB signaling \[[@R16]\] resulting in cytokine production but not degranulation \[[@R15]\].

In contrast, IL-3 is crucial to promote differentiation, survival, and proliferation of mast cells \[[@R17]--[@R19]\]. IL-3 activates STAT3/5, JNK1/2, ERK1/2, PI3Ks and mTOR \[[@R17], [@R20], [@R21]\]. Impairment of these signaling cascades decreases mast cell numbers in peripheral tissues, compromises bacterial clearance and weakens type I hypersensitivity \[[@R17], [@R20], [@R22]--[@R24]\].

Recent publications reported a crosstalk between FcεRI either with TLRs (including TLR4) or c-Kit resulting in increased NFκB-, NFAT- or JNK activation and cytokine production \[[@R25], [@R26]\]. We found an crosstalk between activated c-Kit and the IL-1R or the IL-33R \[[@R27], [@R28]\] resulting in potentiated cytokine production in response to IL-1 or IL-33. Here, we identify a novel mechanism by which IL-3 induces IKK activation which mediates mitogenic signaling in primary- and tumor mast cells and modulates the full biological response of IL-33.

RESULTS {#s2}
=======

IL-3-induced IKK activation in BMMC {#s2_1}
-----------------------------------

IL-3 induced IKK activation results in anti-apoptotic signaling in hepatocytes \[[@R29]\]. We found that IL-3 also induces IKK activation, IκBα phosphorylation but not degradation in BMMCs (Figure [1A](#F1){ref-type="fig"}). To exclude defective IKK-IκBα signaling we used IL-33, a known activator of IKK-dependent IκBα degradation. In contrast to IL-3, IL-33 induced IκBα degradation and cytokine response in BMMCs which was blocked by treatment with the IKK-inhibitor VII (Figure [1B](#F1){ref-type="fig"} and [1C](#F1){ref-type="fig"}), the most efficient IKK inhibitor tested ([Supplementary Figure S1A--D](#SD1){ref-type="supplementary-material"}).

![The IL3-induced IKK activation does not mediate IκBα degradation\
**(A, B)** BMMCs were stimulated with IL-3 **(A, B)** or IL-33 **(B)** Lysates were analyzed by westernblotting. **(C)** BMMCs were stimulated with IL-3 or IL-33. Supernatants were collected and analyzed for IL-6. **(D--F)** NFκB-EGFP-MC/9 cells were pre-incubated with the IKK-inhibitor VII and stimulated with IL-3 or IL-33. Lysates were analyzed by westernblotting **(D)** or cells were analyzed for EGFP-production by flow cytometry **(E)** or collected supernatants were analyzed for IL-6 **(F)**](oncotarget-06-5354-g001){#F1}

Next we used NFκB-EGFP-MC/9 \[[@R30]\] mast cells to examine whether IL-3 induces NFκB activation. Confirming the results in BMMCs, IL-3 did not induce IκBα degradation (Figure [1D](#F1){ref-type="fig"}), EGFP expression (Figure [1E](#F1){ref-type="fig"}) or an effective cytokine-production (Figure [1F](#F1){ref-type="fig"}). Again, IL-33 elicited all these effects in an IKK-dependent manner (Figure [1D](#F1){ref-type="fig"}--[1F](#F1){ref-type="fig"}). Thus, IL-3 does not induce the canonical NFκB signaling. Why does the IL-3-induced IKK activation fail to activate NFκB? When cells were cultured with cycloheximide, an inhibitor of protein biosynthesis, IL-3 induced a mild but detectable IκBα degradation ([Supplementary Figure S1E](#SD1){ref-type="supplementary-material"}). This finding indicates that IL-3 can induce some IκBα degradation. In presence of ongoing IκBα re-synthesis, this IL-3-induced IκBα degradation is quantitatively not sufficient to result a net loss of IκBα. Therefore, we propose the term "subthreshold activation" to describe IKK activation which suffices to phosphorylate IκBα but is insufficient to trigger NFκB activation.

Subthreshold IKK2 activation is critical for IL-3-induced proliferation {#s2_2}
-----------------------------------------------------------------------

Having shown that the IL-3-induced subthreshold IKK activation does not result in efficient cytokine production, we asked if IKKs mediate the activation of the mitogenic JNK signaling \[[@R24]\]. Indeed, the IKK-inhibitor VII potently impaired the IL-3-induced activation of JNKs and the phosphorylation of IκBα (Figure [2A](#F2){ref-type="fig"}). Consequently, the IKK-inhibitor VII blocked the IL-3-induced proliferation (Figure [2B](#F2){ref-type="fig"}) and BMMC expansion (Figure [2C](#F2){ref-type="fig"}) without inducing cell death (Figure [2D](#F2){ref-type="fig"}). When IKK-inhibitor VII-treated BMMC were washed and re-stimulated with IL-3, their proliferative capacity was restored (Figure [2E](#F2){ref-type="fig"}).

![The IL-3-induced IKK2 activation mediates mitogenic signaling\
**(A, B)** BMMCs were pre-incubated with the IKK-inhibitor VII and were stimulated with IL-3. Lysates were analyzed by westernblotting **(A)** or cells were probed with \[H^3^\]thymidine and analyzed by *β*-counting **(B)** (*p* \< 0,001). **(C, D)** BMMCs were pre-treated with the IKK-inhibitor VII (2,5 μM) and stimulated with IL-3. BMMCs were treated with toloduine blue **(C)** or PI **(D)** and viable cells were counted **(C)** (*p* \< 0,01) or cells were analyzed by flow cytometry **(D)**. **(E)** IKK-inhibitor VII-treated (2,5 μM) BMMCs were cultured with IL-3 (for 48 h), washed, re-stimulated with IL-3 (for 4 days), probed with \[H^3^\]thymidine and analyzed by *β*-counting. **(F, G)** *Ikk2^F/F^* or *Ikk2^Δ^* BMMCs were stimulated with IL-3. Cells were probed with \[H^3^\]thymidine and analyzed by *β*-counting **(F)** (*p* \< 0,001) or lysates were analyzed by westernblotting **(G)**.](oncotarget-06-5354-g002){#F2}

To confirm the results obtained by pharmacological inhibition of IKKs, we induced IKK2-deficiency by injection of *Ikk2^Δ^*-mice with poly(I:C) \[[@R31]\]. Consequently, the IL-3-induced proliferation and JNK activation was reduced in *Ikk2^Δ^*-BMMC compared to *Ikk2^F/F^*-BMMCs (Figure [2F](#F2){ref-type="fig"} and [2G](#F2){ref-type="fig"}).

The IL-3-induced proliferation depends on JNK1 {#s2_3}
----------------------------------------------

Next, we investigated whether the IKK-dependent JNK signaling is relevant for the IL-3-induced BMMC proliferation. The JNK inhibitor SP600125 significantly reduced the IL-3-induced proliferation (Figure [3A](#F3){ref-type="fig"}) without inducing cell death (Figure [3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}). To determine which JNK isoform is relevant for the IL-3-induced proliferation we used *Jnk1^−/−^*-, *Jnk2^−/−^*- and *Jnk3^−/−^*-BMMCs. BMMCs do not express JNK3 ([Supplementary Figure S2A--C](#SD1){ref-type="supplementary-material"}). The surface expression of IL-3Rα is equal in wt, *Jnk1^−/−^*- and *Jnk2^−/−^*-BMMCs ([Supplementary Figure S2D](#SD1){ref-type="supplementary-material"}). *Jnk1^−/−^*-BMMC proliferated less strongly (Figure [3D](#F3){ref-type="fig"}) in response to IL-3 than wt- or *Jnk2^−/−^*-BMMCs (Figure [3E](#F3){ref-type="fig"}). Together these data indicate that the IL-3-induced proliferation depends on an IKK2-JNK1 signaling pathway.

![JNK1 and SFKs mediate the IL-3-induced mitogenic signaling\
**(A--C)** BMMCs were pre-treated with SP600125. Cells were probed with \[H^3^\]thymidine **(A)** or PI **(B, C)** and were analyzed by *β*-counting **(A)** or flow cytometry **(B, C)**. **(D, E)** Wt, *Jnk1^−/−^* **(D)** or *Jnk2^−/−^* **(E)** BMMCs were stimulated with IL-3. Cells were probed with \[H^3^\]thymidine and analyzed by *β*-counting. **(F, G)** BMMCs were pre-treated with SU6656 and were stimulated with IL-3. Cells were probed with \[H^3^\]thymidine and analyzed by *β*-counting **(F)** (*p* \< 0,001) or lysates were analyzed by westernblotting **(G)**.](oncotarget-06-5354-g003){#F3}

Subthreshold IKK activation is SFK-dependent and primes mast cells for NFκB-dependent effector functions {#s2_4}
--------------------------------------------------------------------------------------------------------

Next we investigated which pathway mediates subthreshold IKK activation. Given that the Malt/Bcl10-complex \[[@R32]\] and MyD88 (data not shown) are not involved we examined SFKs, critical for IKK2 activation and for mitogenic signaling \[[@R33]--[@R37]\]. The SFK inhibitor SU6656 blocked the IL-3-induced proliferation and inhibited the IL-3-induced JNK activation and IκBα phosphorylation (Figure [3F](#F3){ref-type="fig"} and [3G](#F3){ref-type="fig"}). In contrast, the IL-33-induced IKK activation was not affected by SU6656 ([Supplementary Figure S3A](#SD1){ref-type="supplementary-material"}) indicating that the SFK-dependent IKK activation is specific for the IL-3-induced signaling.

SCF potentiates the IL-33-induced cytokine response in BMMCs \[[@R27]\]. Hence, we tested whether the IL-3-induced subthreshold IKK activation primes BMMCs for stronger NFκB activation upon IL-33R-signaling. Indeed, co-stimulation with IL-3 and IL-33 increased the IκBα phosphorylation, accelerated its degradation (Figure [4A](#F4){ref-type="fig"}) and potentiated the IL-6 mRNA production ([Supplementary Figure S3B](#SD1){ref-type="supplementary-material"}) compared to IL-33 alone. Consequently, IL-6 production after co-stimulation was much stronger than in response to IL-33 alone (Figure [4B](#F4){ref-type="fig"}). Notably, TNFα and IL-13 were only produced when BMMCs were co-stimulated with IL-3 and IL-33 but were not detectable upon stimulation with IL-33 alone (Figure [4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}). Confirming the priming effect of IL-3, the full potentiated cytokine response was only detectable, when cells were first stimulated with IL-3 followed by exposure to IL-33. Pre-stimulation with IL-33 or simultaneous stimulation with IL-3 and IL-33 induced only a partial co-stimulatory effect ([Supplementary Figure S3C](#SD1){ref-type="supplementary-material"}).

![IL-3 primes BMMCs for stimulation with IL-33\
**(A, B)** BMMCs were single stimulated with IL-33 or IL-33 in combination with IL-3. Lysates were analyzed by westernblotting **(A)** or collected supernatants were analyzed for IL-6 **(B)** (*p* \< 0,001). **(C, D)** BMMCs were single stimulated with IL-33 or IL-33 in combination with IL-3. Supernatants were collected and analyzed for TNFα **(C)** (*p* \< 0,001) or IL-13 **(D)** (*p* \< 0,001). **(E, F)** BMMCs were pre-treated with the IKK-inhibitor VII **(E)** or SU6656 **(F)**. Cells were single stimulated with IL-33 or IL-33 in combination with IL-3. Collected supernatants were analyzed for IL-6 (**E**, **F**; *p* \< 0,001). **(G)** Wt or *Jnk1^−/−^* BMMCs were single stimulated with IL-33 or IL-33 in combination with IL-3. Supernatants were collected and analyzed for IL-6.](oncotarget-06-5354-g004){#F4}

Furthermore, cyclohexamide, MyD88-deficiency ([Supplementary Figure S3D and S3E](#SD1){ref-type="supplementary-material"}), the IKK-inhibitor VII (Figure [4E](#F4){ref-type="fig"}) and (5Z)-7-Oxozeaenol (TAK1 inhibitor) (data not shown) completely blocked the IL-33- and IL-3/IL-33-induced cytokine production. In contrast, the SFK-inhibitor SU6656 only reduced the cytokine production (Figure [4F](#F4){ref-type="fig"}) whereas JNK1-deficiency (Figure [4G](#F4){ref-type="fig"}) had no effect. These data show that the *de novo* synthesis of cytokines induced by IL-33 or IL-33 in combination with IL-3, strictly depends on the MyD88-TAK1-IKK2 signaling whereas SFKs have only modulatory functions. Thus, whereas the IL-3-induced and SFK-dependent JNK1 activation mediates proliferation it does not influence the IL-33-induced cytokine production.

IL-3-induced mast cell priming also depends on Ca^2+^ {#s2_5}
-----------------------------------------------------

Ca^2+^ mediates IL-3-inudced signaling \[[@R38]\] and is important for TNFα-induced IKK activation \[[@R37]\]. We investigated whether Ca^2+^ also mediates the IL-3-induced subthreshold IKK activation and consequently induces mast cell priming.

The Ca^2+^ chelator BAPTA-AM blocked the IL-3-induced IKK activation (Figure [5A](#F5){ref-type="fig"}), the IL-33-induced canonical NFκB signaling and cytokine production in BMMCs (Figure [5B](#F5){ref-type="fig"} and [5C](#F5){ref-type="fig"}) and NFκB-EGFP-MC/9 cells ([Supplementary Figure S4A and S4B](#SD1){ref-type="supplementary-material"}). This shows that Ca^2+^ is critical for the IL-3- and IL-33-induced IKK activation. Next we investigated the role of Ca^2+^ by using ionomycin. We used suboptimal ionomycin concentrations that neither induces NFAT activation nor cytokine production \[[@R39], [@R40]\] ([Supplementary Figure S4C](#SD1){ref-type="supplementary-material"}). Combined with IL-33, 2 ng ionomycin showed the most pronounced potentiated IL-6 production (Figure [5D](#F5){ref-type="fig"}) which was blocked by BAPTA-AM, the IKK-inhibitor VII and was reduced by SU6656 (Figure [5E](#F5){ref-type="fig"}--[5G](#F5){ref-type="fig"}). Therefore, ionomycin mimics IL-3 stimulation and potentiates the IL-33-induced cytokine production.

![Ca^2+^ mediates the IL-3-induced mast cell priming\
**(A, B)** BMMCs were pre-treated with BAPTA-AM and stimulated with IL-3 **(A)** or IL-33 **(B)**. Lysates were analyzed by westernblotting. **(C)** BMMCs were pre-treated with BAPTA-AM and single stimulated with IL-33 or IL-33 in combination with IL-3. Supernatants were collected and analyzed for IL-6 (*p* \< 0,001). **(D)** BMMCs were pre-treated with different ionomycin concentrations and stimulated with IL-33. Supernatants were collected and analyzed for IL-6. **(E--G)** BMMCs were pre-treated with BAPTA-AM **(E)** the IKK-inhibitor VII **(F)** or SU6656 **(G)** (E, G; *p* \< 0,001). Cells were single stimulated with IL-33 or IL-33 in combination with ionomycin. Supernatants were collected and analyzed for IL-6. Wt, *Pld1^−/−^* **(H)** or U73122 **(I)** -treated BMMCs were single stimulated with IL-33 or IL-33 in combination with IL-3. Supernatants were collected and analyzed for IL-6 (**I**; *p* \< 0,001).](oncotarget-06-5354-g005){#F5}

Ca^2+^ mobilization induces NFAT activation. Thus, we tested whether stimulation with IL-33 alone or in combination with IL-3 induces NFAT activation. Neither IL-33 nor IL-33 in combination with IL-3 induced NFAT activation in NFAT-EGFP-MC/9 cells compared to ionomycin ([Supplementary Figure S4D--F](#SD1){ref-type="supplementary-material"}). These data show that Ca^2+^ is critical for the induced cytokine production independently of NFAT.

The Orai1/STIM1-Ca^2+^-channel system is important for FcεRI-mediated mast cell effector functions \[[@R41]\]. Therefore we hypothesized that the IL-33- and/or the IL-3/IL-33-induced cytokine production also depends on Orai1 and Stim1. Neither Orai1- ([Supplementary Figure S4G](#SD1){ref-type="supplementary-material"}) nor STIM1- (data not shown) deficiency affected the IL-33- or IL-3/IL-33-induced cytokine production.

The IL-3-induced Ca^2+^ mobilization depends on PLCγ \[[@R38]\]. In contrast, IL-33 does not induce PLCγ activation (data not shown) but was reported to induce a PLD1-dependent Ca^2+^ mobilization resulting in NFκB activation \[[@R42]\]. Neither treatment of NFκB-EGFP-MC/9 cells with the PLD1 inhibitor CAY10594 ([Supplementary Figure S4H](#SD1){ref-type="supplementary-material"}) nor PLD1 deficiency (Figure [5H](#F5){ref-type="fig"}) influenced NFκB activation or cytokine production. As expected the PLCγ inhibitor U-73122 did not affect the IL-33-induced cytokine response but blocked the potentiated cytokine response induced by co-stimulation with IL-3 and IL-33 (Figure [5I](#F5){ref-type="fig"}).

These data indicate that the IL-3-induced PLCγ activation and the resulting Ca^2+^ mobilization are crucial for mast cell priming and the resulting potentiated cytokine production.

Subthreshold IKK activation mediates survival of tumor mast cells {#s2_6}
-----------------------------------------------------------------

In primary mast cells, IKK inactivation reduced the IL-3-induced mitogenic signaling. IL-3, c-Kit and IKKs are involved in pathogenesis of a number of malignancies \[[@R43]--[@R45]\]. Therefore, we determined the activation status of IKKs and their relevance for survival and proliferation in tumor mast cells. The v-HA-*Ras*-transformed V2D1 murine tumor mast cells constitutively produces IL-3, resulting in autocrine stimulation, proliferation and survival \[[@R46]\]. In these cells we found an increased JNK activation and IκBα phosphorylation but no degradation excluding the production of cytokines that activate NFκB (Figure [6A](#F6){ref-type="fig"}).

![Survival of V2D1 cells depends on the IKK-mediated IL-3 production\
**(A)** V2D1 cells were cultured in IL-3-free medium for different time periods. Lysates were analyzed by westernblotting. **(B--D)** V2D1 cells were treated with the IKK-inhibitor VII. Lysates were analyzed by westernblotting **(B)** or cells were probed with \[H^3^\]thymidine **(C)** or PI **(D)**. Cells were analyzed by *β*-counting **(C)** or by flow cytometry **(D)** (**C**; *p* \< 0,001). **(E)** V2D1 cells were treated with the IKK-inhibitor VII and collected supernatants were analyzed for IL-3 (*p* \< 0,001). **(F)** V2D1 cells were treated with the IKK-inhibitor VII and stimulated with IL-3. Cells were probed with \[H^3^\]thymidine and were analyzed by *β*-counting (*p* \< 0,01).](oncotarget-06-5354-g006){#F6}

The IKK-inhibitor VII blocked the activation of JNKs, the phosphorylation of IκBα (Figure [6B](#F6){ref-type="fig"}) and consequently reduced cell proliferation (Figure [6C](#F6){ref-type="fig"}) by inducing cell death (Figure [6D](#F6){ref-type="fig"}). This demonstrates the relevance of IKKs in V2D1 cells. Given that survival of V2D1 cells depends on IL-3 production we speculated that IKKs are involved in IL-3 production and that exogenous IL-3 rescues V2D1 cells from cell death induced by IKK inhibition. As shown in Figure [6E](#F6){ref-type="fig"} IL-3 production is reduced by IKK inhibition. Moreover, the IKK-inhibitor VII-induced cell death can be reversed by exogenous IL-3 (Figure [6F](#F6){ref-type="fig"}). These data show that subthreshold IKK activation is important for IL-3 production to mediate mitogenic signaling in V2D1 cells.

Inhibition of IKKs reduces tumor growth *in vivo* {#s2_7}
-------------------------------------------------

To analyze tumor growth *in vivo*, we used DBA/1-*Rag1^−/−^*-mice (Figure [7A](#F7){ref-type="fig"}). We injected 1 × 10^6^ V2D1 mast cells subcutaneously. After 7 days, a 25 μM IKK-inhibitor VII solution or vehicle was injected intratumorally for 6 weeks. As shown in Figure [7B](#F7){ref-type="fig"} and [7C](#F7){ref-type="fig"} tumor size was significantly decreased in mice treated with the IKK-inhibitor. Cells obtained from an explanted tumor still expressed c-Kit, IL-3Rα, and IL-33R (Figure [7D](#F7){ref-type="fig"}) and showed IKK-dependent IL-3 production (Figure [7E](#F7){ref-type="fig"}) and proliferation (Figure [7F](#F7){ref-type="fig"}). These data verify that the explanted cancer cells are still dependent on IL-3 production for autocrine stimulation and survival.

![IKK inhibition reduced growth of V2D1 tumors\
**(A)** Blood from wt or DBA1-*Rag1^−/−^*-mice was analyzed for CD3 and B220. **(B)** V2D1-cells (1 × 10^6^) were injected subcutaneously into the flanks of DBA/1-*Rag1^−/−^*-mice and tumor area was assessed for 6 weeks using a Mitutoyo Quick Mini caliper. Growing tumors were either treated with DMSO/PBS (blue line) or with IKK-inhibitor VII (red line) (25 μM). \[Data represent the mean SD of 10 mice with tumors (*p* \< 0,001)\]. **(C)** V2D1 tumor size after 5 weeks, (upper panel) treated with vehicle DMSO/PBS and (lower panel) treated with IKK-inhibitor VII. **(D)** Cells from an explanted tumor were analyzed for surface expression of c-Kit, IL-3Rα and IL-33R. **(E)** Explanted cells were left untreated or were treated with the IKK-inhibitor VII. Supernatants were collected and analyzed for IL-3 (*p* \< 0,01). **(F)** Explanted cells were treated with the IKK-inhibitor VII, were probed with \[H^3^\]thymidine and analyzed by *β*-counting (*p* \< 0,001).](oncotarget-06-5354-g007){#F7}

DISCUSSION {#s3}
==========

We identified IKKs as important for IL-3-induced mitogenic signaling in BMMCs. Hitherto, IKK2 has been known as an important component in the signaling pathways emanating from receptors such as antigen receptors, TIR- and TNFR-superfamily family members \[[@R32], [@R47]\]. In all of these cases, IKK2 activation results in IκBα degradation and NFκB activation \[[@R48]\]. In contrast to the canonical pathway, we found that IL-3 induced only a weak and transient subthreshold IKK activation, which resulted in IκBα phosphorylation without IκBα degradation and without NFκB activation.

The major questions are (i) how does IL-3 induce subthreshold IKK2 activation?; and (ii) why is there no IκBα degradation and NFκB activation? Neither MyD88- nor Malt1- or Bcl10-deficiency influence the IL-3-induced mast cell proliferation \[[@R32]\]. Instead, our data indicate a critical role of SFKs and Ca^2+^ for the IL-3-induced subthreshold IKK activation. We hypothesize that the combined activation of SFKs, PLCs and a Ca^2+^-dependent PKC-isoform mediates subthreshold IKK2 activation.

These data indicate that components (e.g., the MyD88-IRAK-TAK1-signaling module) critical for effective IκBα phosphorylation and degradation are not activated. Therefore the IL-3-induced IKK activation is only sufficient to induce mitogenic signaling, but is below the threshold to induce IκBα degradation and NFκB activation. Although the reason for the missing IκBα degradation is still unknown we suggest that IκBα degradation occurs to some extent upon IL-3 stimulation but is quantitatively not sufficient to induce a net loss of IκBα in the presence of ongoing IκBα re-synthesis.

Additionally, the IL-3-induced subthreshold IKK activation primes mast cells for enhanced NFκB activation in response to IL-33. This shows that mast cells integrate signals from different receptors which activate IKKs. Thereby, both, the IL-3-induced and SFK-mediated, and the IL-33-induced but MyD88-IRAK-TAK1-dependent pathways are crucial to facilitate full IKK2 activity.

Therefore the signal strength determines the effector functions resulting from IKK activation. Weak, subthreshold, IKK activation as induced by IL-3 suffices to induce proliferation but not NFκB activation. Stronger IKK activation as provided by IL-33 signaling results in NFκB activation and production of cytokines. Combined signaling via IL-3 and IL-33 results in proliferation and strongly enhanced cytokine production. Under homeostatic conditions IL-3 serves as growth and survival factor for mast cells. Under pathological conditions (tissue damage) the presence of the alarmin IL-33 dramatically alters the mast cells\' response to IL-3 which now becomes much more pro-inflammatory (IL-6, TNFα, IL-13).

In tumor cells, dysregulated expression of IL-3 is the molecular basis for survival and proliferation \[[@R11], [@R43], [@R46], [@R49]\] leading to malignancies, including mast cell leukemia (MCL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). In such cells subthreshold IKK activation might be a prerequisite for permanent proliferation. Indeed, pharmacological inhibition of subthreshold IKK activation specifically reduces tumor growth *in vivo*. Since IKK inhibition induced cell death in tumor- but not in primary-cells, IKK-inhibition could be a powerful approach to specifically eliminate certain tumor cells. In summary, our data indicate that the IL-3-induced subthreshold IKK activation is an important mechanism that mediates pathological effector functions in inflamed tissues after infection, allergy, necrosis and supports survival of tumor cells. Therefore, inhibition of subthreshold IKK activation might be a potential and selective tool to treat such mast cell driven diseases.

METHODS {#s4}
=======

Mice {#s4_1}
----

Animal experiments were approved by the appropriate institutional and governmental committees for animal welfare. The xenograft model was performed in accordance with institutional guidelines on animal welfare and was approved by the "Landesamt für Natur, Umwelt und Verbraucherschutz" of Nordrhein-Westfalen (AZ 2011.A302). We used sex- and age-matched *Myd88^−/−^*, *Jnk1^−/−^* \[[@R50]\], *Jnk2^−/−^* \[[@R50], [@R51]\], *Jnk3^−/−^* \[[@R50], [@R52]\], *Ikk2^F/F^* \[[@R31]\], *Ikk2^Δ^* \[[@R31]\], *Pld1^−/−^* \[[@R53]\], *Orai1^−/−^* \[[@R54]\], *Stim1^−/−^* \[[@R41], [@R55]\], DBA1-*Rag1^−/−^*-mice and wild type (wt) littermates for generation of bone marrow-derived mast cells (BMMCs) or to perform the xenograft model.

Cell culture {#s4_2}
------------

For BMMCs generation bone marrow was obtained from the femurs and tibias of mice. Bone marrow cells were cultured in IMDM (PAA) supplemented with 10% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, 50 mM 2-mercaptoethanol (complete medium) and 20 ng/ml mIL-3 (conditioned media from WEHI-3 cells). Mast cells were identified by expression of FcεRI, c-Kit, IL-33R and IL-3Rα by flow cytometry. The mast cell lines NFκB- and NFAT-EGFP-MC/9 (Dr. E. A. Barbu, Receptors and Signal Transduction Section, NIDCR, National Institutes of Health, Bethesda, Maryland, USA; \[[@R30]\]) were cultured in complete DMEM (PAA) supplemented with 20 ng/ml mIL-3 (conditioned media from WEHI-3 cells). V2D1-cells (Dr. Moroni, Department of Biochemistry, University of Basel, Switzerland; \[[@R46]\]) were cultured in complete IMDM (V2D1).

Flow cytometry {#s4_3}
--------------

Non-specific binding was blocked with anti-CD16/CD32 (clone 2.4G2) and rat-IgG (Jackson). Cells were stained with biotinylated anti-murine IL-33R antibody (3E10; \[[@R56]\]), PE-conjugated streptavidine, the APC-conjugated anti-CD123 antibody (R&D Systems), the PE-conjugated anti-murine CD117 antibody (Biolegend) or the anti-murine FcεRI antibody (FITC-conjugated) (eBioscience) (in PBS containing 0.25% BSA and 0.02% sodium azide).

For EGFP-production, NFκB- or NFAT-EGFP-MC/9 cells (10^6^ cells/ml) were IL-3-starved (1 h), pre-treated with inhibitors (30 min) and stimulated with IL-3 or IL-33 (8 h) (both Peprotech). After harvesting and washing (PBA-buffer; 0.25% BSA and 0.02% sodium azide in PBS) cells were analyzed by using an LSR II flow cytometer (BD) and FlowJo 8.1.1 (Treestar Inc.).

Stimulation and lysis {#s4_4}
---------------------

BMMCs (10^6^ cells/ml) were IL-3-starved (1 h), pre-incubated (30 min) with SP600125 (JNK-inhibitor), SU6656 (SFK-inhibitor), IKK-inhibitors (VII, PS-1145, BMS-34554) and U73122 (PLC inhibitor) (If not other stated all these inhibitors were used in a concentration of 5 μM). Furthermore we used the protein biosynthesis inhibitor cyclohexamide (340 μM), the PLD1 inhibitor CAY10594 (10 μM), and the Ca^2+^ chelator BAPTA-AM (10 μM) or ionomycin (in a concentration from 0,5--10 ng/ml) (all inhibitors were from Merck Millipore). After pre-incubation of the indicated inhibitor cells were stimulated with IL-3 and/or IL-33 (Peprotec., in a concentration of 50 ng/ml). V2D1 cells were seeded (10^6^ cells/ml), pre-treated with the IKK-inhibitor VII (1 h). Cells were lysed (in 20 mM HEPES, pH7.5; 10 mM EGTA; 40 mM β-glycerophosphate; 2.5 mM MgCl~2~; 2 mM orthovanadate; 1 mM dithiothreitol; 20 μg/ml aprotinin; 20 μg/ml leupeptin, 1% Triton). Protein concentration was determined by using the BCA-assay (Pierce) and samples were boiled in 6 x Laemmli buffer.

q PCR {#s4_5}
-----

Cells stimulated with IL-3 and/or IL-33 were pelleted and lysed with TRIzol (life technologies). RNA was extracted according to the manufacturer\'s protocol. Total RNA (2 μg) was reverse transcripted using oligo(dT)-primers, the M-MLV reverse transcriptase (affymetrix), RNase inhibitor (Promega) and the PCR thermocycler (Biometra). For the quantitative IL-6 real-time PCR the 5′ primer TCTCTGCAAGAGACTTCCATCCAGT and the 3′ primer AGCCTCCGACTTGTGAAGTGGT were used. The quantitative real-time PCR was performed with the KAPA SYBR fast kit (peqlab) according to the manufacturer\'s guidelines in an ABI Step OnePlus Real-Time PCR System (life technologies). GAPDH real-time PCR was performed by using the 5′ primer TTGGCCGTATTGGGCGCCTG and the 3′ primer CACCCTTCAAGTGGGCCCCG. Relative gene expression was determined using the conventional ßßCT method setting the control (unstimulated samples) as 1.

Immunoblotting {#s4_6}
--------------

Samples were separated on 10% sodium dodecyl sulfate (SDS)-Laemmli gels and transferred by electroblotting onto nitrocellulose membranes (Biostep). Membranes were blocked in 0.1% Tween/TBS-buffer with 5% dry milk and incubated with antibodies detecting phosphorylated/non-phosphorylated proteins. We used anti-pT183/Y185-JNK-1/2/JNK-1/2, anti-pS176/177-IKK1/2/IKK1/2, anti-pT345/S346-IRAK4, anti-pS32-IκBα/IκBα, anti-PLD1 and anti-tubulin (Cell Signaling; except anti-IKK1/2 from Santa Cruz and anti-tubulin from Sigma). Membranes were washed in 0.1% Tween/TBS and incubated with HRP-conjugated secondary antibodies: anti-rabbit-Ig, anti-goat-Ig (Santa Cruz) and anti-mouse-Ig (Thermo). Detection was performed using ECL reagent (Pierce).

Cell death and cell counting {#s4_7}
----------------------------

10^6^ cells/ml (BMMCs) or 10^5^ cells/ml (V2D1) were pre-treated with the IKK-inhibitor VII or SP600125 (48 h), harvested, washed (PBA-buffer) and treated with propidium iodide (PI). Cells were analyzed with the LSR II flow cytometer (BD) and FlowJo 8.1.1 (Treestar Inc.).

For cell counting BMMCs (10^6^ cells/ml) were seeded in IL-3-free media. After 1 h cells were treated with IKK-inhibitor VII (for 30 min) and were stimulated with IL-3 as indicated. Cells were 1:1 mixed with trypan blue solution and trypan blue-negative cells were counted by using Neubauer counting chamber.

ELISA and proliferation assays {#s4_8}
------------------------------

BMMCs (10^6^ cells/ml) or V2D1 (10^5^ cells/ml) were seeded in IL-3-free media. Cells were incubated with vehicle (DMSO) or inhibitors. BMMC were stimulated with IL-3, IL-33 or both (Peprotech). Supernatants were analyzed for IL-3, IL-6, TNFα and IL-13 using matched pair antibodies (eBioscience) by ELISA. For proliferation assays cells were cultured for 54 h. \[H^3^\]thymidin (1 μCi) was added for additional 18 h. Incorporated radioactivity was measured by using a *β*-scintillation counter (Perkin Elmer). The increase of mast cell proliferation is indicated as the stimulation index (SI). Thereby the basal CPM values were set to 1.

Characterization of DBA/1-*Rag1*^−/−^-mice {#s4_9}
------------------------------------------

Blood was taken from facial vein from 4--6 week old mice. After lysis of erythrocytes, samples were washed in PBA, stained with anti-CD3 (clone 145--2C11, ebioscience, Germany) and anti-B220 (clone RA3--6B2) and analyzed with the LSR II flow cytometer (BD, USA) and FlowJo (Treestar Inc., USA).

Xenograft tumor model {#s4_10}
---------------------

DBA/1-*Rag1^−/−^*-mice (10--18 weeks old) received 10^6^ V2D1-cells in 100 μl subcutaneously into the shaved flanks. Animals were treated 3 times weekly with vehicle (1% DMSO/PBS) or the IKK-inhibitor VII (100 μl; 25 μM in 1% DMSO/PBS) subcutaneously around the tumors. Tumor size was assessed 3 times weekly by using a Mitutoyo Quick Mini caliper (Mitutoyo). Measurements were recorded as tumor area (mm^2^) from groups of 10 mice. Tumor area (A) was calculated by the formula: \[A = tumor height x tumor width\]. Experiments were terminated after 6 weeks or if tumor size exceeded the ethically approved dimensions.

Statistics {#s4_11}
----------

All experiments were performed at least three times (shown is one representative experiment). Proliferation assays, and ELISAs were performed three times in at least a 6-fold determination. Cytokine concentration is indicated as the mean of measurements ± standard deviation. For proliferation assays and ELISA one representative experiment is shown. The statistical analysis was performed with IBM SPSS Statistics version 20.0 (IBM). Statistical significance was assessed by Mann-Whitney-U test. Statistical significance was accepted for *p* \< 0,05 (\*,*p* \< 0.05; \*\*,*p* \< 0.01; \*\*\*,*p* \< 0.001).

SUPPLEMENTARY FIGURES {#s5}
=====================
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